CD8A and neoplasm: Finally, CD4+ and CD8+ T cells assessment at day 20 post-tumor injection showed a five-fold increase of the CD8+ T immune cells in the C51 FL Rnaset2 group, as shown in Figure 5D, indicating a potential Rnaset2-mediated anti-tumor role of these cells as effector cytolytic immune cells.